Clinical correlates of <i>JAK2</i>V617F allele burden in essential thrombocythemia
Jaya Kittur(Mayo Clinic), Ayalew Tefferi(Mayo Clinic in Arizona), Wenting Wu(Wenzhou Institute of Industrial Science), Alexandra P. Wolanskyj(Mayo Clinic), Animesh Pardanani(Palmetto Hematology Oncology), Christy M. Finke(Mayo Clinic), Rhett P. Ketterling, Ryan A. Knudson(Mayo Clinic), Naseema Gangat(Mayo Clinic), Chin‐Yang Li(Mayo Clinic), Terra L. Lasho(Mayo Clinic)
Cited by 154
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907